EN
投资者关系

代谢性疾病

标题 发表场所 类型 时间
GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice 2025年肥胖周
（ObesityWeek® 2025）		 海报 11/2025
A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity 2025年肥胖周
（ObesityWeek® 2025）		 海报 11/2025
ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity:A Ph Ib Study 2025年肥胖周
（ObesityWeek® 2025）		 海报 11/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study 第61届欧洲糖尿病研究协会
（EASD 2025）		 简短口头报告 9/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model 美国糖尿病协会第85届科学会议
（ADA 2025）		 海报 6/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study 美国糖尿病协会第85届科学会议
（ADA 2025）		 海报 6/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study 第32届欧洲肥胖症大会 （ECO 2025） 引导型海报 5/2025
ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice 第32届欧洲肥胖症大会 （ECO 2025） 口头报告 5/2025

拓展性适应症

标题 发表场所 类型 时间
Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial 欧洲皮肤病学和性病学会杂志 论文 11/2025
First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase Ⅲ Randomised Placebo Controlled Trial 2025年欧洲皮肤病与性病学会（EADV）年会 口头报告 9/2025
First FASN inhibitor ASC40 to treat acne vulgaris patients: final results from a Phase 2 trial 2024年美国皮肤病学会（AAD）年会 海报 3/2024
ASC40， an oral once-daily fatty acid synthase (FASN) inhibitor, in patients with acne vulgaris: topline results from a phase 2 randomized, double-blind, placebo-controlled, multicenter trial 2023年欧洲皮肤病与性病学会（EADV）大会 海报 10/2023

  • © 2018 Ascletis Pharma Inc.

contact

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号 浙ICP备11050387号-1